Minerva Neurosciences, Inc. (NERV) is a clinical-stage biopharmaceutical company focused on developing a portfolio of product candidates targeting central nervous system (CNS) diseases. Since its establishment, the company has devoted its energy towards creating innovative solutions for significant unmet medical needs in the domain of neurology, proving to be a trailblazer in its field.
Headquartered in Waltham, Massachusetts, Minerva Neurosciences is well-known for its significant contribution to neuroscience through advanced therapies and medications. The company's philosophy is centered on utilizing innovative technology and clinical science to bring forth novel treatments that can enhance patients' lives and provide an advantageous alternative to the existing treatments available for neurological disorders.
Under its umbrella, Minerva Neurosciences has several product candidates in various stages of clinical development. These include roluperidone (MIN-101) for the treatment of schizophrenia, seltorexant (MIN-202) in collaboration with Janssen Pharmaceutica, for insomnia disorder and Major Depressive Disorder (MDD), MIN-117 for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease. The advancement and development of these treatments serve as a testament to the company’s focus on enhancing neurological health on a wide scale.
Minerva Neurosciences, Inc. operates under a highly-experienced leadership team with a wealth of knowledge and experience in biopharmaceutical development. With deep-rooted expertise in discovering, developing, and commercializing novel therapeutics, the team is continually driving the company's mission forward to disrupt the healthcare sphere with powerful solutions for CNS conditions.
The company's stock trades on the NASDAQ under the symbol "NERV." Since its initial public offering in 2014, Minerva Neurosciences has grown significantly, with steady growth in its operations, clinical trials, and revenues, reflecting its continual commitment to transforming the landscape of neurology.
By investing in advanced research and focusing on patient needs, Minerva Neurosciences, Inc. continues to pave the way for innovative treatments in the field of neurology. The company is committed to uplifting the standard of care and improving the quality of life for patients coping with CNS diseases. While their path is laden with the typical risks and challenges associated with drug development, the potential to revolutionize the treatment of neurological disorders could have a far-reaching impact on global healthcare.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Minerva Neurosciences, Inc. (Nasdaq: NERV) announced its participation in two upcoming investor conferences: the Wells Fargo Healthcare Conference on September 8, 2026, and the Cantor Global Healthcare Conference on September 9, 2026. Management will hold 1x1 meetings at both events, and a fireside chat will be featured at the Cantor conference. The company is a clinical-stage biopharmaceutical firm focusing on treatments for central nervous system disorders and is currently conducting a Phase 3 trial for roluperidone.
Minerva Neurosciences (Nasdaq: NERV) reported its second quarter 2026 financial results, highlighting the ongoing confirmatory Phase 3 trial of roluperidone (MIN-101C19) for negative symptoms of schizophrenia, with topline efficacy data expected in 2H 2027. The company also announced the expansion of its Scientific Advisory Board and provided detailed financial figures, including a GAAP net income of $17.5 million for the quarter driven by a non-cash gain from warrant liability. Roluperidone remains the only late-stage drug candidate specifically targeting negative symptoms in schizophrenia.
Zacks Research has downgraded Minerva Neurosciences (NASDAQ:NERV) to a "strong sell" rating, citing weak earnings forecasts despite the company beating Q2 analyst expectations. The biopharmaceutical company's shares opened at $3.92, significantly below its 52-week high, and institutional investors hold a 34.56% stake. Analysts project continued losses for NERV in 2026 and 2027, with some positive long-term EPS forecasts for 2029 and 2030.
Minerva Neurosciences, Inc (NASDAQ:NERV) has received a "Reduce" consensus rating from brokerages, with an average 12-month price target of $10.50. This comes as near-term earnings expectations have significantly deteriorated, with HC Wainwright cutting its fiscal 2026 and 2027 EPS estimates, although it projects profitability by 2029. Despite these lowered forecasts, Minerva Neurosciences recently beat analyst estimates for its quarterly loss, reporting -$0.14 EPS against an expected -$0.19.
HC Wainwright has revised its Q3 2026 EPS estimate for Minerva Neurosciences (NASDAQ:NERV) to a loss of $0.14 per share, a significant reduction from its previous forecast of a $0.01 loss. The firm also projects a $0.50-per-share loss for the full fiscal year 2026, with further negative revisions for 2027, though long-term estimates for 2029 and 2030 show potential for recovery. Minerva Neurosciences recently reported a narrower-than-expected quarterly loss of $0.14 per share, but its stock was trading down 6.5% at $4.32, well below its 12-month high.